CLINICAL TRIALS PROFILE FOR BETAXOLOL HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for betaxolol hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000132 ↗ | Early Manifest Glaucoma Trial (EMGT) | Unknown status | National Eye Institute (NEI) | Phase 3 | 1992-10-01 | The primary purpose is to compare the effect of immediate therapy to lower the intraocular pressure (IOP) versus late or no treatment on the progression of newly detected open-angle glaucoma, as measured by increasing visual field loss and/or optic disc changes. The secondary purposes are to determine the extent of IOP reduction attained by treatment, to explore factors that may influence glaucoma progression, and to describe the natural history of newly detected glaucoma. |
| NCT01660620 ↗ | Topical Betaxolol for the Prevention of Retinopathy of Prematurity | Completed | Ohio State University | Phase 1 | 2011-04-01 | We hypothesize that topical betaxolol will reduce the development of severe retinopathy of prematurity. |
| NCT01660620 ↗ | Topical Betaxolol for the Prevention of Retinopathy of Prematurity | Completed | The University of Texas Health Science Center, Houston | Phase 1 | 2011-04-01 | We hypothesize that topical betaxolol will reduce the development of severe retinopathy of prematurity. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for betaxolol hydrochloride
Condition Name
Clinical Trial Locations for betaxolol hydrochloride
Trials by Country
Clinical Trial Progress for betaxolol hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for betaxolol hydrochloride
Sponsor Name
